The article investigates whether illness beliefs and beliefs about rehabilitation are predictors of short and middle term outcome in depression even when adjustments are made for variables, which are known to be predictors of the course of depression. Within the context of a non-controlled prospective study design, data were analyzed using forced entry hierarchical multiple regression analyses. The sample comprised N = 98 patients. Adjusting for a range of sociodemographic and medical predictors, illness beliefs and beliefs about rehabilitation predict outcome in depression. Illness beliefs and beliefs about rehabilitation are relevant starting points for designing patient-oriented interventions.
1 March 2013 in Journal of Rehabilitation Medicine
Hintergrund und Fragestellung: Die Berücksichtigung der Ko- bzw. Multimorbidität von Patienten ist - gerade im Kontext der Rehabilitation - von hoher Bedeutung. Zur Messung von Multimorbidität existieren international einige etablierte Indices. Ein diesbezügliches Instrument mit explizitem Rehabilitationsbezug wurde jedoch bislang - im deutschsprachigen Raum - nicht publiziert. Im vorliegenden Beitrag wird daher ein generisches, rehabilitationsspezifisches Assessmentinstrument zur Erfassung von Ko- bzw. Multimorbidität mit Fokus auf die Funktionsfähigkeit vorgestellt („KoMo-Score”) und im Hinblick auf methodische Gütekriterien evaluiert. Methoden: Der KoMo-Score wurde unter Berücksichtigung etablierter Komorbiditätsindices entwickelt und liegt in einer Arzt- und in einer Patientenversion vor. Die erfassten Begleiterkrankungen können zu einem Summenscore „Anzahl Erkrankungen”, einem „Schweregradscore”, einem „Einschränkungsscore” sowie einem „Komorbiditäts-Gesamtscore” aggregiert werden. Die Überprüfung methodischer Gütekriterien der Arztversion umfasst Analysen zur Praktikabilität, Konstruktvalidität, konkurrenten und prädiktiven Validität. Die Datenerhebung erfolgte an N=998 stationären Rehabilitanden aus neun Kliniken und N=654 ambulanten Rehabilitanden aus sieben Reha-Zentren, jeweils mit der Indikation Muskuloskelettale Erkrankungen. Ergebnisse: Die Praktikabilität des KoMo-Scores wird durch die geringe Anzahl fehlender Werte sowie eine konsistente Bearbeitungsweise belegt. Zusammenhänge mit dem Alter und der Eingangsbelastung weisen auf die Konstruktvalidität des Instruments hin, während die konkurrente Kriteriumsvalidität durch erwartungskonforme Unterschiede zwischen ambulanten und stationären Rehabilitanden untermauert wird. Hinweise auf die prädiktive Validität des Scores ergeben sich durch das Aufzeigen prädiktiver Relevanz der Multimorbidität sowohl im Hinblick auf die Eingangsbelastung als auch bezüglich des Outcomes einer Rehabilitationsmaßnahme. Schlussfolgerung: Die vorliegenden Daten weisen auf die Praktikabilität und Validität des rehabilitationsbezogenen KoMo-Scores hin. Künftige Fragestellungen bestehen in der weitergehenden Prüfung des Scores im Hinblick auf die Interrater-Reliabilität und Test-Retest-Reliabilität sowie in der Überprüfung der parallel entwickelten Patientenversion des Instruments. Background and purpose: It is extremely important to consider the comorbidity and multimorbidity of patients - especially for rehabilitation. There are some internationally established indexes for measuring multimorbidity. However, such an instrument designed explicitly for rehabilitation has not yet been published in the German-speaking world. In this article, a generic, rehabilitation-specific instrument to assess comorbidity and multimorbidity with a focus on functionality (“KoMo score”) is introduced and evaluated as to the method's quality criteria. Methods: The KoMo score was developed using established comorbidity indexes and is available in a physician and a patient version. The concomitant diseases surveyed can be aggregated to a “total number of diseases” score, a “degree of severity” score, a “activity limitations” score, and a “total comorbidity” score. The examination of the quality criteria of the physician version includes analyses of practicability, construct validity, and concurrent and predictive validity. The data were collected from N=998 inpatient rehab subjects at nine clinics and N=654 out-patient rehab subjects at seven rehabilitation centers, all of whom were being treated for musculoskeletal diseases. Results: The practicability of the KoMo score is shown by the low amount of missing values and a consistent approach. Correlations with age and baseline health status are an indication of the construct validity of the instrument, while the concurrent criterion validity is supported by anticipated variations between outpatient and inpatient rehab subjects. Demonstrating the predictive relevance of multimorbidity both in terms of baseline health status and of the outcome of rehabilitation gives evidence for the predictive validity of the score. Conclusion: These data are an indication of the practicability and validity of the rehabilitation KoMo score. Future areas for research include the further testing of the score, for example with respect to inter-rater reliability and test-retest-reliability, as well as assessing the patient version of the instrument developed in parallel with the physician version.
Background: Mobile health apps have great potential to support the self-management of chronic conditions such as allergic diseases, which constitute significant challenges in health care. However, the health app market is confusing for users, as it is vast, dynamic, and lacks scientific evidence regarding the effectiveness of the apps on offer. To our knowledge, no health app for pollen-related allergic rhinitis has been evaluated. Objective: The aim of our study was to evaluate the Husteblume mobile phone health app, developed in Germany to facilitate the self-management of pollen-related allergic rhinitis. Methods: We evaluated usability and changes in quality of life, health literacy, and self-efficacy for managing one’s chronic disease. We conducted 2 online surveys of registered users of the app, 1 before and 1 after the 2017 pollen season, allowing for the analysis of both cross-sectional and longitudinal data in a field setting. Results: The sample comprised 661 app users at the first measurement point and 143 users at follow-up. The subgroup of study participants at follow-up rated the usability of the app as good or very good. There were no significant changes in patient-reported outcomes such as quality of life, health literacy, and self-efficacy between the 2 measurement points (P>.05). However, those reached at follow-up perceived subjective improvements due to the app: 55.9% (80/143) reported being subjectively better informed about their allergy, 27.3% (39/143) noted improved quality of life, 33.6% (48/143) reported subjectively better coping with their allergy, and 28.0% (40/143) felt better prepared for the consultation with their physician. Finally, 90.9% (130/143) users did not identify any adverse effects of the app. Conclusions: Despite some methodological caveats, the results of the evaluation of the Husteblume app are encouraging for the subgroup using the app in the long term. However, further studies evaluating the effectiveness of the app are needed. Trial Registration: German Clinical Trials Register DRKS00011897; https://tinyurl.com/yxxrg9av